BofA update shows where active managers are putting money
Yea Christopher, chief development officer of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), sold 2,649 shares of common stock on August 18, 2025, at a price of $13.187 per share, for a total transaction value of $34,932. The transaction comes as the $631 million market cap biotech company trades near $12.81, having gained over 57% year-to-date. According to InvestingPro analysis, the stock appears slightly overvalued at current levels.
On August 17, 2025, Yea also acquired 4,203 shares of Common Stock. In addition, Christopher exercised options for 1,773 and 2,430 Restricted Stock Units of KalVista Pharmaceuticals. With the company’s next earnings report due on September 4, investors tracking insider activity can access additional insights through InvestingPro, which features 8 more key tips about KALV’s financial health and market position.
In other recent news, KalVista Pharmaceuticals announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of sebetralstat, an oral treatment for hereditary angioedema (HAE) attacks. If approved by the European Commission, sebetralstat will become the first oral on-demand treatment for HAE available in the European Union. The UK has already granted marketing authorization for EKTERLY (sebetralstat), marking it as the first oral treatment for HAE attacks in patients aged 12 years and older. This approval provides the drug with up to 10 years of market exclusivity in the UK. JMP Securities has reiterated its Market Outperform rating and $27.00 price target on KalVista Pharmaceuticals, citing the potential of the on-demand HAE market. The firm maintains its positive outlook following the UK approval of the treatment. In related updates, Metagenomi has appointed Laurence Reid, PhD, to its Board of Directors, bringing 30 years of biotech experience to the company. Reid also holds board positions at several other biotechnology firms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.